Traders should monitor enrollment and event accumulation rates in the DECLARATION study, as well as regulatory interactions for VMS063. The delay in VYD2311 results reduces near-term catalyst visibility, while VMS063 represents a high-risk, high-reward pipeline expansion into a new indication.
IVVD drugs
IVVD drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 9 $1.78entry
- T+1 · 7mo ago −1.12%α −1.06% · $1.76
- T+5 · 7mo ago −3.93%α −7.12% · $1.71
- T+20 · 6mo ago −17.98%α −25.55% · $1.46
- T+60 · 4mo ago −53.15%α −63.93% · $0.8340
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Invivyd announced progress in its Phase 3 DECLARATION study for VYD2311, including a pre-specified upsizing by ~500 subjects to ensure robust statistical power, pushing top-line results to Q3 2026. The company also announced the advancement of VMS063, a novel measles monoclonal antibody candidate, with IND readiness targeted for late 2026.
Key Facts
- DECLARATION Phase 3 study upsized by ~500 subjects, increasing total enrollment beyond initial 1,818.
- Top-line results for VYD2311 now expected in Q3 2026, a two-month delay from prior 'mid-year' guidance.
- FDA alignment on initial Pediatric Study Plan (DRUMMER trial) for VYD2311 in children aged 0-11, contingent on adult trial success.
- VMS063, a novel measles mAb candidate, advanced toward IND-enabling studies with target IND readiness in late 2026.
- No clinical efficacy or safety data reported for either VYD2311 or VMS063; all updates are developmental and forward-looking.
Financial Impact
No immediate financial impact disclosed; long-term value hinges on successful development and regulatory approval of VYD2311 and VMS063.
Risk Factors
- Delayed timeline for VYD2311 results increases uncertainty and extends cash runway needs.
- VMS063 is in early development with no clinical data; high risk of failure in later stages.
- Forward-looking statements dominate; lack of concrete data limits near-term upside.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3270803 |
Track record
19 reports on IVVD
3 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +35.85% at T+20 after the Jul 6, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 16, 2026today Press Release Neutral 6/10 Entry $0.5603 Now $0.5380 −3.98% settles Nov 23
- Nov 3, 202613d ago Press Release Neutral 2/10 Entry $0.5815 to $0.5744 Now $0.5380 −7.48% ▼ −1.22% −0.63% vs SPY
- Sep 29, 20266w ago 8-K Bullish 7/10 Entry $0.8501 to $0.8064 Now $0.5380 −36.71% ▼ −5.14% −7.09% vs SPY
- Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $0.9640 to $0.8501 Now $0.5380 −44.19% ▼ −11.82% −10.63% vs SPY
- Sep 1, 202610w ago 8-K Neutral 6/10 Entry $0.8800 to $0.7973 Now $0.5380 −38.86% ▼ −9.40% −9.48% vs SPY
- Aug 17, 202613w ago 144 Neutral 2/10 Entry $0.8680 to $0.9387 Now $0.5380 −38.02% ▲ +8.15% +8.35% vs SPY
- Jul 6, 202619w ago 8-K Bearish 6/10 Entry $0.8340 to $0.7834 Now $0.5380 +35.49% ▲ +6.07% +6.56% vs SPY
- Jun 16, 202621w ago Press Release Neutral 5/10 Entry $0.8918 to $0.9346 Now $0.5380 −39.67% ▲ +4.80% +7.03% vs SPY
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $0.8125 to $0.9312 Now $0.5380 −33.78% ▲ +14.61% +14.18% vs SPY
- Jun 9, 202622w ago Press Release Neutral 4/10 Entry $0.9900 to $0.8686 Now $0.5380 −45.66% ▼ −12.26% −14.67% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers